Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.84
-0.0200-0.52%
Post-market: 3.840.00000.00%19:47 EDT
Volume:786.21K
Turnover:3.01M
Market Cap:120.15M
PE:-0.93
High:3.90
Open:3.90
Low:3.75
Close:3.86
52wk High:50.40
52wk Low:3.60
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.97
T/O Rate:4.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.55
PE(LYR):-1.35

Loading ...

Press Release: Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Dow Jones
·
Sep 29

Chardan Trims Price Target on CAMP4 Therapeutics to $6 From $6.50, Keeps Buy Rating

MT Newswires Live
·
Sep 29

Summit Therapeutics secures major AstraZeneca equity partnership

TIPRANKS
·
Sep 29

Summit Therapeutics price target raised to $43 from $40 at Citi

TIPRANKS
·
Sep 29

Chimeric Therapeutics Seeks ASX Quotation for 29.3 Million New Shares

TIPRANKS
·
Sep 29

Thalia Therapeutics Secures Chinese Patent for Lead AML Drug miRisten

TIPRANKS
·
Sep 29

Top Executive Makes Bold Insider Move at Damora Therapeutics

TIPRANKS
·
Sep 29

Addex Therapeutics Earnings Call Highlights Pipeline Upside

TIPRANKS
·
Sep 29

Closing Bell Movers: Summit Therapeutics jumps on AstraZeneca investment

TIPRANKS
·
Sep 29

Defence Therapeutics Advances Oncology Strategy and Tightens Leadership Alignment

TIPRANKS
·
Sep 29

Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment

TIPRANKS
·
Sep 29

Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

TIPRANKS
·
Sep 29

AstraZeneca makes $2B equity investment in Summit Therapeutics

TIPRANKS
·
Sep 29

Tempest Therapeutics Strengthens Governance and CAR-T Partnership Framework

TIPRANKS
·
Sep 29

Mirum Therapeutics Reaffirmed as Top Pick as Analyst Hikes Price Target to $195 on Strong Clinical and Regulatory Wins

TIPRANKS
·
Sep 29

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

GlobeNewswire
·
Sep 28

Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial

TIPRANKS
·
Sep 28

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

GlobeNewswire
·
Sep 28

Press Release: Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Dow Jones
·
Sep 28